. Detachment from ECM is associated with enhanced production of reactive oxygen species (ROS) owing to altered glucose metabolism 2 . Here we identify an unconventional pathway that supports redox homeostasis and growth during adaptation to anchorage independence. We observed that detachment from monolayer culture and growth as anchorage-independent tumour spheroids was accompanied by changes in both glucose and glutamine metabolism. Specifically, oxidation of both nutrients was suppressed in spheroids, whereas reductive formation of citrate from glutamine was enhanced. Reductive glutamine metabolism was highly dependent on cytosolic isocitrate dehydrogenase-1 (IDH1), because the activity was suppressed in cells homozygous null for IDH1 or treated with an IDH1 inhibitor. This activity occurred in absence of hypoxia, a wellknown inducer of reductive metabolism. Rather, IDH1 mitigated mitochondrial ROS in spheroids, and suppressing IDH1 reduced spheroid growth through a mechanism requiring mitochondrial ROS. Isotope tracing revealed that in spheroids, isocitrate/citrate produced reductively in the cytosol could enter the mitochondria and participate in oxidative metabolism, including oxidation by IDH2. This generates NADPH in the mitochondria, enabling cells to mitigate mitochondrial ROS and maximize growth. Neither IDH1 nor IDH2 was necessary for monolayer growth, but deleting either one enhanced mitochondrial ROS and reduced spheroid size, as did deletion of the mitochondrial citrate transporter protein. Together, the data indicate that adaptation to anchorage independence requires a fundamental change in citrate metabolism, initiated by IDH1-dependent reductive carboxylation and culminating in suppression of mitochondrial ROS.
activity, as demonstrated previously during matrix detachment 3 . Indeed, inhibitory PDH phosphorylation and expression of PDH kinase-1 (PDK1) were elevated in spheroids (Fig. 1c) . Citrate labelling from [U- 13 C]glutamine persisted in spheroids, but the 13 C distribution was altered, particularly in that the m+5 fraction (the fraction containing five 13 C nuclei) exceeded m+4 (Fig. 1d ). This persisted when cells were disaggregated and permitted to reform spheroids (Extended Data Fig. 2e ). The m+5 fraction appeared rapidly and endured as the most prominent labelled form (Fig. 1e) , regardless of the type of culture medium (Supplementary Table 1; this Table contains all   13 C data throughout the paper). Because PDH inhibition can alter glutamine 13 C] glucose and unlabelled glutamine (n = 3 cultures from a representative experiment). b, Oxygen consumption rates (OCR) of cells grown in monolayer or spheroid culture (n = 10 monolayer cultures and 11 spheroids from a representative experiment). c, Western blot for total (t) and phosphorylated (p, Ser 293) PDH, and PDH kinase-1 (PDK1). d, Mass isotopologue analysis of citrate in cells cultured with [U- 13 C]glutamine and unlabelled glucose (n = 3 cultures from a representative experiment). e, Evolution of citrate mass isotopologues in spheroids cultured with [U- 13 C]glutamine (n = 2 cultures for each time point). f, Citrate m+4 and m+5 isotopologues in monolayer and spheroid cultures of A549, HT-29 and MCF7 cells cultured with [U- 13 C]glutamine (n = 3 A549 monolayer cultures; n = 4 cultures for all other conditions). Complete mass isotopologue distributions are shown in Supplementary Table 1. All data represent mean ± s.d. *P < 0.05, Welch's unequal variances t-test. All experiments were repeated 3 times or more.
Letter reSeArCH metabolism 4 , we examined the effect of the PDK1 inhibitor dichloroacetate (DCA), which activates PDH, on 13 C labelling. DCA enhanced glucose-dependent citrate labelling and reduced the m+5 fraction from [U- 13 C]glutamine (Extended Data Fig. 2f ), indicating that m+5 citrate resulted from reduced PDH activity.
Culture with [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]glutamine demonstrated that spheroids induced reductive glutamine metabolism to generate isocitrate/citrate (Extended Data Fig. 3a ). Reductive citrate labelling was observed in spheroids from multiple lung, colon and breast cancer cell lines (Fig. 1f ) . However, labelling of other TCA cycle intermediates predominantly reflected oxidative (m+4) rather than reductive (m+3) metabolism (Extended Data Fig. 3b ). To test whether reductive metabolism occurred in non-transformed cells, we compared [U- 13 C]glutamine metabolism between lung cancer cells and nonmalignant bronchial epithelial cells (BECs) from the same patient 5 . Cancer cells but not BECs displayed enhanced citrate m+5 labelling upon detachment (Extended Data Fig. 3c ).
Reductive carboxylation is enhanced during hypoxia through a HIF1-dependent mechanism that transmits glutamine carbon to fatty acids 6 . Although large spheroids contain gradients of oxygenation, reductive labelling occurred in spheroids much smaller than the limit of oxygen diffusion 7 ( Fig. 2a, b) , and hyperoxia did not normalize citrate m+5 (Extended Data Fig. 4a ). We detected neither HIF1α 
Letter reSeArCH stabilization nor staining with a hypoxia probe in spheroids cultured under 21% oxygen (Fig. 2c, d ). Furthermore, although large spheroids contain gradients of nutrient availability 8 , experimentally reducing glucose/glutamine availability did not increase citrate m+5 (Extended Data Fig. 4b ). Most compellingly, detachment without aggregation was sufficient to enhance citrate m+5 (Fig. 2e) , and spheroids lost the reductive pattern when allowed to adhere to plastic (Extended Data  Fig. 4c) . Hypoxia elicited numerous labelling changes distinct from patterns observed in normoxic spheroids (Extended Data Fig. 5a and Supplementary Discussion). Remarkably, reductive citrate labelling was not associated with increased contribution of glutamine to palmitate unless the spheroids were cultured under hypoxia (Extended Data Fig. 5b ). Glucose was the predominant lipogenic carbon source in both monolayer and spheroid cells (Extended Data Fig. 5c ). Acetate, a source of lipogenic acetyl-CoA in hypoxia 9 , was only a minor source of lipogenic carbon in normoxic H460 spheroids (Extended Data Fig. 5d ). Together, these data suggest that anchorage loss per se rather than oxygen/nutrient limitation stimulates a mode of reductive metabolism distinct from hypoxia.
We next used metabolic flux analysis to better understand the metabolic effects of anchorage loss. Steady state fluxes were calculated by integrating extracellular flux rates and 13 C distributions in several metabolites from multiple tracers (see Methods and Supplementary  Tables 2 and 3 ). Modelling with a set of conventional reactions and compartmentation did not produce an adequate fit for the spheroid data (Extended Data Fig. 6a ). This was related to discrepant labelling between citrate, which contained evidence of enhanced reductive carboxylation, and palmitate, which did not. To rectify this discrepancy, we modified the model to force isocitrate/citrate produced reductively in the cytosol into the mitochondria, as if by channelling (Extended Data Fig. 6b ). This pool then mixed with mitochondrial isocitrate/ citrate before being used for fatty acid synthesis in the cytosol. This modification greatly improved the model's ability to fit the data, with the resulting fit indicating persistent but reduced glycolysis, PDH flux and glucose/glutamine oxidation in spheroids, as well as an enhanced reductive IDH flux in the cytosol (Extended Data Fig. 6b and Extended Data Table 1 ). The model also indicated bidirectional isocitrate/citrate traffic across the mitochondrial membrane, with net flux in the direction of export to the cytosol.
Mammals contain three IDH isoforms. IDH1 and IDH2 catalyse the reversible, NADP + /NADPH-dependent interconversion of isocitrate and α-ketoglutarate in the cytosol and mitochondria, respectively, and participate in reductive carboxylation 10 . IDH3 is mitochondrial, NAD + -dependent and essentially irreversible 11 . To determine the roles of all three isoforms in spheroids, CRISPR/Cas9 was used to generate H460 clones lacking each one. IDH1 or IDH2 knockout reduced citrate m+5, although the effect of IDH1 was more pronounced (Fig. 3a, b) . Deleting IDH3 caused a large accumulation of citrate (Fig. 3c ), whereas deleting IDH1 or IDH2 had only minor effects on citrate abundance (Extended Data Fig. 7a ). Thus, IDH3 is primarily responsible for citrate oxidation in the TCA cycle, whereas IDH1 is primarily responsible for reductive carboxylation. Like IDH1 deletion, an IDH1 inhibitor (compound 321) 12 eliminated the spheroids' gain in citrate m+5 and enhanced the m+4 fraction ( Fig. 3d and Extended Data Fig. 7b-e) . The drug had no effect on citrate m+5 in IDH1-deleted spheroids, consistent with its selectivity for IDH1 (Extended Data Fig. 7e ).
Because reductive citrate metabolism was not associated with enhanced palmitate labelling from glutamine, we tested whether citrate was transported into mitochondria, as predicted by the model. Citrate export to the cytosol through a citrate transporter protein (CTP) encoded by SLC25A1 is a key component of lipogenesis 13 , but Letter reSeArCH mitochondrial citrate import has also been reported 14 . We prepared mitochondria from H460 cells containing or lacking CTP and examined their ability to metabolize citrate (Extended Data Fig. 8a, b) . CTP-wild type mitochondria took up [U- 13 C]citrate and converted it to succinate, fumarate and malate, with the majority of these intermediates labelled as m+4 in the first turn of the TCA cycle ( Fig. 3e and Extended Data Fig. 8c ). Adding unlabelled glutamine and pyruvate to [U- 13 C]citrate resulted in m+2 labelling from multiple turns (Fig. 3e and Extended  Data Fig. 8d) . Labelling from [U- 13 C]citrate was essentially absent in CTP-deficient mitochondria, even though [U- 13 C]glutamine was metabolized normally (Fig. 3e and Extended Data Fig. 8c-e) .
In non-transformed breast epithelial cells, matrix detachment enhances ROS by reducing pentose phosphate pathway (PPP) activity, but oncogenes sustain the PPP and viability during detachment 2 . Transgenic reporters that sense ROS in either the cytosol or mitochondria 15 revealed that detachment increased ROS in both compartments, but particularly the mitochondria (Fig. 4a) . IDH1 knockout (Fig. 4b) or inhibition with 321 (Fig. 4c) further increased mitochondrial ROS, consistent with a pathway in which isocitrate/citrate is formed through NADPH-dependent reductive carboxylation in the cytosol, followed by metabolism of one or both metabolites in the mitochondria to produce NADPH and fortify ROS defences ( Fig. 4d and Extended Data Fig. 1b) . Consistent with this model, both the PPP inhibitor dehydroepiandrosterone (DHEA) and IDH2 knockout enhanced mitochondrial ROS ( Fig. 4e and Extended Data Fig. 9a ). IDH1 knockout reduced cytosolic ROS, suggesting that PPP-derived NADPH is repurposed to counteract cytosolic ROS in the absence of IDH1 (Extended Data Fig. 9b ). CTP knockout enhanced mitochondrial ROS without affecting cytosolic ROS, as predicted if mitochondrial isocitrate/citrate import generates reducing equivalents to mitigate mitochondrial ROS (Fig. 4f) .
To examine reducing equivalent metabolism, H460 cells were cultured with H]glucose, which labels cytosolic NADPH via the PPP, but does not transfer 2 H to TCA cycle metabolites in monolayer culture 16 . We generated parental, IDH1-and IDH2-knockout H460 cells expressing a mutant IDH2 that produces 2-hydroxyglutarate (2HG) in an NADPH-dependent mitochondrial reaction. Thus, 2 H labelling of 2HG reflects mitochondrial NADPH labelling 16 . As expected, citrate was not labelled from H]glucose in monolayer cells. However, spheroids contained substantial citrate labelling that required IDH1 but not IDH2 (Fig. 4g) and was suppressed by DHEA (Extended Data Fig. 9c) . Similarly, 2HG was essentially unlabelled in monolayer cells, but labelling was evident in spheroids; here, labelling required both IDH1 and IDH2 (Fig. 4g ). All these data are consistent with the pathway in Fig. 4d .
Finally, CTP-, IDH1-and IDH2-deficient cells were challenged to grow as spheroids. CTP deletion suppressed growth in both monolayer and spheroids, reflecting the transporter's dual roles in lipogenesis and ROS mitigation (Extended Data Fig. 9d ). By contrast, IDH1 and IDH2 were dispensable in monolayers, but loss of either enzyme suppressed average spheroid size by half (Fig. 4h ) and growth could be partially rescued with the mitochondrial ROS scavenger MitoTEMPO (Extended Data Fig. 9e ). Treatment with 321 also reduced spheroid size, and this was completely rescued by MitoTEMPO or N-acetylcysteine (NAC) (Fig. 4i) .
Protection against oxidative stress is thought to be one aspect of metabolic reprogramming that supports cancer cell fitness [17] [18] [19] . Anchorage independence induces additional oxidative stress resulting in death unless NADPH-producing pathways are engaged 2 . The finding that cytosolic IDH1 is required to regulate mitochondrial ROS was surprising. IDH1 and IDH2 participate in a cycle transmitting NADPH from mitochondria to cytosol 20 . Our data suggest that this pathway also operates in reverse to transfer reducing equivalents from the PPP into the mitochondria. This pathway enables an alternative form of redox regulation and suggests a possible metabolic intervention to suppress anchorage independence. The importance of this pathway for redox homeostasis is remarkable, considering that the net direction of citrate trafficking in spheroids is from the mitochondria to the cytosol to supply fatty acid synthesis. The isocitrate/ citrate fluxes responsible for ROS mitigation may arise from metabolite compartmentation involving mechanisms yet to be characterized. The data imply that limiting mitochondrial rather than cytosolic oxidative stress is crucial for anchorage independence, because IDH1 loss enhanced the former while reducing the latter, culminating in reduced spheroid size.
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Reagents. MitoSOX Red mitochondrial superoxide indicator was from Life Technologies. MitoTEMPO, N-acetylcysteine (NAC), Nocodazole, DHEA and DCA were from Sigma. The IDH1 inhibitor 321 and control compound 990 were from GlaxoSmithKline 12 .
Cell lines and culture. Cell lines were identified using DNA fingerprinting and confirmed to be mycoplasma free. H460, A549, HBEC30 and HCC4017 cells were provided by J. D. Minna, UT Southwestern. MCF7 cells were provided by David A. Boothman, UT Southwestern. HT-29 cells were provided by Jared Rutter, University of Utah. H460 and A549 cells were cultured in RPMI supplemented with penicillin/streptomycin, 5% fetal bovine serum (FBS), l-glutamine (4 mM) and 1 mM HEPES. HT-29 and MCF7 were cultured in DMEM supplemented with penicillin/streptomycin, 10% fetal bovine serum (FBS), l-glutamine (4 mM) and 1 mM HEPES. HBEC30 and HCC4017 cells were cultured in defined medium 5 . Dishes with an Ultra-Low Attachment surface were used for suspension and spheroid culture. Identical culture medium was used for monolayer and spheroid culture. For spheroids, 2 × 10 5 H460 cells were plated in a 10 cm Ultra-Low Attachment dish. The medium was changed on days 4, 6 and 7 of culture, by centrifuging at 50g for 3 min, then gently resuspending in fresh medium. For labelling assays, the spheroids were resuspended in medium containing 13 C-labelled nutrients, and the time of resuspension was considered time 0 of the labelling period. CRISPR/Cas9-mediated recombination. IDH1, IDH2, IDH3 and SLC25A1-deficient H460 cell lines were generated using the CRISPR/Cas9 system 21 . Wild type clones were selected from both the control vector (Vector) and targeting vector transfections (WT). In order to control for variations among individual clones, 4 to 5 clones were pooled together, and different pools for each targeted gene were used for further experiments. Cell growth assays. Cell proliferation was measured by counting cells after trypsinization. DNA content was also used to monitor monolayer cell growth, as previously described 22 . Spheroid size was determined by measuring the maximum cross-sectional area of individual spheroids using ImageJ software. Metabolic assays and stable isotope tracing in intact cells. Glucose, lactate, glutamine and glutamate were measured in culture medium using an automated electrochemical analyser (BioProfile Basic-4 analyser, NOVA). Ammonia was measured using an enzymatic assay (Megazyme). Nutrients labelled with 13 C, 2 H or 15 N were purchased from Cambridge Isotope Laboratories. Stable isotope tracing experiments to determine isotopologue distributions in soluble metabolites and fatty acids were performed as described previously 22, 23 . For deuterium tracing, H460 clones were engineered to express the IDH2-R172K mutant (mtIDH2) under control of doxycycline 16 . Clones lacking wild-type IDH1 or IDH2, or containing both, were generated. Spheroids were cultivated for 7 days, then doxycycline (0.2 μg ml −1 ) was added for 24 h to induce mtIDH2. On day 8, spheroids were cultured in RPMI containing 10 mM [3-2 H]glucose and unlabelled glutamine for 6 h. Mitochondria isolation and isotope tracing. Mitochondria were prepared with the Qproteome Mitochondria Isolation Kit (Qiagen). Isotope tracing was modified from a previously described procedure 22 . Mitochondrial pellets were reconstituted in assay buffer (125 mM KCl, 10 mM Tris/MOPS, 0.1 mM EGTA/ Tris, 1 mM P i , pH 7.4) supplied with indicated nutrients and tracer. For glutamine tracing, 40 μM [U- 13 C]glutamine and 40 μM unlabelled pyruvate were added to the assay buffer. For citrate tracing, 40 μM [U- 13 C]citrate with or without 40μM unlabelled glutamine and 40μM unlabelled pyruvate were added to the assay buffer. Mitochondria were incubated in the tracing buffer for 10 min, at 30 °C with 500 r.p.m. agitation in a heat block. Metabolic flux analysis (MFA). Steady state metabolic fluxes were calculated by combining extracellular flux rates (glucose/glutamine utilization, lactate/alanine/ glutamate secretion) and 13 C mass isotopologue distributions (MIDs) for citrate, glutamate, fumarate, malate, aspartate and palmitate, using the INCA software package 24 , which applies an elementary metabolite unit framework to efficiently simulate MIDs 25, 26 . We developed reaction networks describing the stoichiometry and carbon transitions of central carbon metabolism (Supplementary Table 2) , with assumptions as previously described 4 and summarized below. Parallel labelling data from cultures fed [1- Table 3 . To ensure that a global minimum of fluxes was identified, flux estimations were initiated from random values and repeated a minimum of 50 times. A chi-square test was applied to test goodness-of-fit, and accurate 95% confidence intervals were calculated by assessing the sensitivity of the sum of squared residuals to flux parameter variations. Extended Data Table 1 contains the degrees of freedom and sum-of-squared residuals (SSR) for the best fit model and the lower and upper bounds of 95% confidence intervals for all fluxes.
MFA procedures and assumptions: (1) During the experiments, cells are at metabolic steady state. (2) 13 CO 2 produced during oxidation reactions is not reincorporated via carboxylation reactions.
(3) Cells are given 24 h to metabolize 13 C substrates. After 24 h, it is assumed that the isotopic labelling has reached steady state.
(4) The metabolites succinate and fumarate are symmetrical and their metabolism through the TCA cycle does not produce a particular orientation.
(5) The metabolites pyruvate, acetyl-CoA, citrate, α-ketoglutarate, malate, fumarate and oxaloacetate are metabolically active in both the cytosol and mitochondria. Malate and α-ketoglutarate are allowed to freely mix between the compartments.
(6) During the extraction process, intracellular pools of metabolites are homogenized. Therefore GC-MS analysis of the isotopic enrichment of these metabolites reflects the mixture of distinct metabolic pools. By employing the INCA platform to perform metabolic flux analysis, it is possible to extract meaningful information from these mixed pools. To do this, the model employs parameters to account for the mixing of mitochondrial and cytosolic metabolites.
(7) For flux calculations in spheroids, it is not possible to reconcile the palmitate and citrate labelling from the glutamine tracers by mixing the citrate pool in cytosol. To achieve adequate fits, isocitrate/citrate generated from cytosolic reductive carboxylation is first allowed to mix with mitochondrial citrate. This mixed pool could then be used for oxidation in the TCA cycle and fatty acid synthesis. Western blotting. Whole cells/spheroids or mitochondrial lysates were prepared in RIPA buffer and quantified using the BCA Protein Assay (Thermo Scientific). Proteins were separated on 4-20% SDS-PAGE gels, transferred to PVDF membranes, and probed with antibodies against IDH1 (ab94571), IDH2 (ab55271), IDH3 (ab58641) from Abcam, PDHα (#459400, Thermo), PDHα-pSer293 (AP1062), GAPDH (AB2302) from Millipore, PDK1 (#3820), Hif1α (#3716) from Cell Signaling, CTP (sc-86392), AIF (sc-13116) from Santa Cruz Biotechnology and Actin (A3853, Sigma). EF5 staining. Day 7 H460 spheroids were cultured under normoxia (21% oxygen) or hypoxia (1% oxygen) for 16 h. The spheroids were then treated with 100 μM EF5 compound for 3 h, fixed in 4% paraformaldehyde, and embedded in OCT for frozen sectioning. 10 μm spheroid sections were stained with EF5 antibody as previously described 27 . Subcellular ROS detection. Cytosolic and mitochondrial ROS levels were measured with the organelle-specific HyPer system as previously described 15, 28 . Briefly, trypsinized H460 cells were transfected with HyPer-cyto or HyPer-mito vectors. Half of the transfected cells were allowed to attach as a monolayer, and the other half were cultured in suspension using Ultra-Low Attachment dishes. Images were acquired 48 h after transfection, and ROS levels were calculated as the ratio of fluorescence at 488 nm and 405 nm. Oxygen consumption rates (OCR). For monolayer respiration assays, H460 cells were plated in growth media at 3 × 10 4 cells per well in XF24 microplates (Seahorse Bioscience; Billerica, MA) 24 h before the assay following manufacturer's recommendations for cell seeding. Growth media was changed to XF assay media and the plates were incubated at 37 °C in a non-CO 2 incubator for 45 min before starting the assay. To normalize the data, the cells were trypsinized and counted by haemocytometer or ViCELL automated cell counter (Beckman Coulter). To measure respiration in spheroids, H460 Spheroids were grown for 3 days in 96-well Ultra-Low Attachment round bottom plates (Sigma; Cat# CLS7007) starting with 2 × 10 3 cells per well, resulting in an average spheroid diameter of 401 ± 13 μm. For the respiration assay, spheroids were transferred to a Poly-d-lysine-treated XFe96 Spheroid Microplate (Seahorse Bioscience cat# 102959-100) containing 37 °C XF assay media at pH 7.4. Following each assay, the spheroid diameter was measured using images acquired on a Cytation 3 Cell Imaging Reader (BioTek; Winooski, VT). Volume was then calculated using the equation v = 4 / 3 πr 3 . To normalize the data, the cell number of each spheroid was calculated by dividing the spheroid volume by the single-cell volume (average diameter of H460 cells = 14 μm). This method of calculating spheroid cell number was independently validated in parallel cultures by digesting spheroids with trypsin and manually counting the cells with a haemocytometer. Determination of wild type IDH1 and IDH2 inhibition. IDH1 was generated as previously described 29 . IDH2 was expressed in Sf 9 cells by baculovirus infection. Cells were lysed in lysis buffer (50 mM Tris, pH 7.5, 300 mM NaCl, 10% glycerol, 1% Triton) by Avestin emulsiflex C50. The supernatants were mixed with anti-Flag resin at 4 °C overnight and then eluted with addition of 100 μg ml −1 Flag peptide in lysis buffer (without Triton). The eluate was concentrated and loaded onto a Superdex 200 size exclusion column and eluted with sizing buffer (25 mM Tris, 100 mM NaCl, 1 mM DTT, pH 7.5). Fractions containing dimer were pooled and concentrated for use in kinetics. IDH activity was assessed by measuring the evolution of NADPH abundance using a coupled diaphorase/resazurin fluorescence assay 30 . Reactions were conducted at room temperature in 384-well Greiner black microtitre plates in a total volume of 10 μl of assay buffer. Final Letter reSeArCH compound concentrations were typically varied from 5 to 100,000 nM; the isocitrate concentration was fixed at 10 μM, the NADP + concentration was fixed at 5 μM, and IDH was fixed at 0.1 nM. Reactions were conducted in quadruplicate and run kinetically. After each addition, plates were centrifuged for 60 s to ensure complete mixing of reagents.
Data were fit to the following equation to determine the IC 50 :
where y is the % of normalized enzyme activity, x is the concentration of inhibitor, and s is the Hill slope factor. Statistics. No statistical methods were used to predetermine sample size. The experiments were not randomized, and the investigators were not blinded to allocation during experiments and outcome assessment. Experiments in Figs 2a, 2b , 4f, and Extended Data Figs 5d, 7d and 8e were performed twice, and all other experiments were performed 3 times or more. Variation is always indicated using standard deviation. To assess the significance of differences among cultures and conditions, a two-tailed Welch's unequal variances t-test was used to assess the significance between two groups. For three or more groups, a one-way ANOVA followed by Dunnett's multiple comparisons test was performed. Before applying ANOVA, we first tested whether there was homogeneity of variation among the groups (as required for ANOVA) using the Brown-Forsythe test. Where the assumption of equal variance was violated, a log 2 transformation was applied to the data before analysis. In a few cases, when significant differences in variation among groups persisted after transformation, we used Welch's unequal variances t-test followed by multiple-comparison correction.
